HIGHOutside partySupplier
single and sole source suppliers
“10-K Item 1A: 'our reliance on a small number of contract manufacturers and a large number of single and sole source suppliers'”
QDEL · Concentration risk · 10-K extracted
QuidelOrtho (QDEL) concentration risks
Updated
The most significant concentration QuidelOrtho discloses is single and sole source suppliers, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: QuidelOrtho’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH1
MEDIUM1
LOW1
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partyCustomer
key distributors
“10-K Item 1A: 'we rely on certain key distributors for the sales of some of our products'”
LOWBuilt-inProduct / Revenue mix
15%
respiratory products
“10-K Item 1A: 'sales of our respiratory products accounted for approximately 15% of our total revenues for the year ended December 28, 2025'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06QuidelOrtho's concentration risk runs through its supply chain more than its customer or product mix. The company discloses reliance on a small number of contract manufacturers and a large number of single and sole source suppliers — a dependency exposure disclosed at a significant scale, with no readily available alternative in place for at least some of these relationships. Layered on top, the company also relies on certain key distributors for the sales of some of its products, a more moderate dependency on the go-to-market side. By contrast, the company's product-line concentration is modest: respiratory products accounted for approximately 15% of total revenues, a comparatively small share of the overall business. Netting these together, the supplier and manufacturer dependency is the most consequential exposure — a disruption at any single- or sole-source supplier could affect production broadly — while the distributor reliance adds a secondary, more moderate dependency on the demand side. The respiratory product concentration, being a modest share of revenue, is unlikely on its own to move the investment verdict.
For the engine’s reasoning on QDEL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| AVNS | Avanos Medical, Inc. | 2 | 0 | 1 | 3 |
| QDEL● | QuidelOrtho Corporation | 1 | 1 | 1 | 3 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AHCO | AdaptHealth Corp. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.